Table 3.
Proportion of days covered and days’ supply during 1 year of follow-up, according to prescription-dispensation and dispensation-only based designs.
| Acenocoum. | Apixaban | Dabigatran | Rivaroxaban | Total OAC | |
|---|---|---|---|---|---|
| Prescription-dispensation cohort (patients with at least one prescription; PD Cohort) | |||||
| n | 29,574 | 2,075 | 3,197 | 3,180 | 38,026 |
| PDC; mean (95% CI) | 96.39 (96.26–96.52) | 95.57 (94.97–96.17) | 95.87 (95.40–96.34) | 94.65 (94.07–95.23) | 96.16 (96.03–96.28) |
| Patients with PDC ≥ 80; % (95% CI) | 94.46 (94.19–94.71) | 93.59 (92.45–94.57) | 93.49 (92.58–94.30) | 92.52 (91.55–93.38) | 94.17 (93.93–94.40) |
| Days’ supply; mean (95% CI) | 305.9 (304.9–306.9) | 322.8 (319.1–326.5) | 297.9 (294.3–301.5) | 307.7 (304.2–311.3) | 306.3 (305.4–307.2) |
| Days’ supply if PDC ≥ 80%; mean (95% CI) | 314.6 (313.6–315.5) | 335.6 (332.4–338.7) | 309.8 (306.5–313.2) | 323.6 (320.6–326.7) | 316.0 (315.2–316.7) |
| Days’ supply if PDC < 80%; mean (95% CI) | 158.6 (154.3–162.8) | 136.7 (120.7–152.6) | 126.0 (113.8–138.1) | 111.1 (98.57–123.7) | 149.1 (145.3–152.9) |
| Dispensation-only cohort (patients with at least one dispensation; D1 cohort) | |||||
| n | 29,411 | 2,047 | 3,162 | 3,124 | 37,744 |
| PDC (mean, 95% CI) | 84.37 (84.10–84.63) | 89.59 (88.62–90.56) | 82.72 (81.77–83.67) | 86.42 (85.51–87.33) | 84.68 (84.44–84.92) |
| Patients with PDC ≥ 80; % (95% CI) | 73.44 (72.93–73.94) | 84.86 (82.23–86.34) | 74.07 (72.51–75.57) | 80.60 (79.18–81.95) | 74.70 (74.26–75.13) |
| Days’ supply; mean (95% CI) | 307.8 (306.9–308.8) | 326.7 (323.1–330.2) | 301.8 (298.3–305.3) | 315.1 (311.7–318.4) | 308.9 (308.1–309.8) |
| Days’ supply if PDC ≥ 80%; mean (95% CI) | 351.2 (350.9–351.5) | 357.2 (356.4–358.1) | 354.1 (353.4–354.9) | 356.4 (355.7–357.2) | 352.3 (352.0–352.5) |
| Days’ supply if PDC < 80%; mean (95% CI) | 187.9 (186.2–187.7) | 155.3 (145.6–165.0) | 152.3 (146.4–158.1) | 143.1 (136.0–150.3) | 181.0 (179.3–182.6) |
| Days’ supply for patients excluded from D1 cohort; mean (95% CI)∗ | 24.3 (12.7–35.9) | 80.3 (31.8–128.8) | 78.5 (32.9–124.0) | 48.9 (19.1–78.8) | 41.5 (29.9–53.1) |
| Dispensation-only cohort (patients with at least two dispensations separated by 6 months; D2 cohort) | |||||
| n | 27,773 | 1,923 | 2,848 | 2,868 | 35,412 |
| PDC; mean (95% CI) | 87.74 (87.52–87.97) | 93.85 (93.20–94.50) | 89.05 (88.32–89.79) | 92.06 91.40–92.71 | 88.53 (88.34–88.73) |
| Patients with PDC ≥ 80; % (95% CI) | 77.75 (77.25–78.23) | 90.22 (88.81–91.47) | 82.19 (80.75–83.56) | 87.69 (86.44–88.84) | 79.59 (79.17–80.00) |
| Days’ supply; mean (95% CI) | 320.2 (319.4–321.0) | 342.4 (340.1–344.8) | 325.0 (322.3–327.7) | 335.9 (333.5–338.3) | 323.1 (322.4–323.8) |
| Days’ supply if PDC ≥ 80%; mean (95% CI) | 351.2 (351.0–351.5) | 357.5 (356.8–358.3) | 354.2 (353.5–354.9) | 356.7 (356.1–357.4) | 352.4 (352.1–352.6) |
| Days’ supply if PDC < 80%; mean (95% CI) | 211.8 (210.2–213.5) | 203.1 (193.0–213.2) | 190.2 (183.3–197.1) | 187.3 (178.4–196.1) | 208.9 (207.3–210.5) |
| Days’ supply for patients excluded from D2 cohort; mean (95% CI)∗∗ | 92.1 (89.1–95.1) | 82.8 (71.4–94.2) | 90.7 (83.8–97.6) | 76.8 (69.1–84.5) | 89.5 (87.0–92.1) |
PDC, proportion of days covered; CI, confidence interval; PDC80, % of patients with PDC values equal or above 80%. ∗282 patients with a prescription excluded from D1 cohort. ∗∗2614 patients that did not filled at least two prescription separated by 6 months excluded from D2 cohort.